fda warning letter hims compounded semaglutide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Hims & Hers Expands Personalized

COA access may be provided through a QR code, report link, or batch documentation page

We believe that weight loss is a marathon, not a sprint, and having 24/7 access to a dedicated team is a vital part of that journey

Cardiovascular and Vascular Research Comprehensive Vascular Protection and Repair Research on component peptides examined effects in various cardiovascular scenarios with complementary mechanisms[17]: BPC-157: Improved healing in vascular anastomosis models and arrhythmia protection TB-500: Enhanced angiogenesis and collateral circulation development GHK-Cu: Support for endothelial function and vascular remodeling KPV: Potential to reduce vascular inflammation Combined approach supports vessel repair, new vessel formation, and inflammation control Studies demonstrated cardioprotective effects in ischemia-reperfusion models, with potential synergy between angiogenic promotion and inflammatory modulation

Metabolism 35 , 944949 (1986)